Ispire Releases 2025 Financial Results: Revenue of $127.5 Million, Net Loss Widens to $39.2 Million

Sep.17.2025
Ispire Releases 2025 Financial Results: Revenue of $127.5 Million, Net Loss Widens to $39.2 Million
Ispire Technology Inc. (NASDAQ: ISPR) announced its financial results for the fiscal year ending June 30, 2025, on September 16, 2025. The report showed that the company's operating revenue was $127.5 million, down from $151.9 million in the previous fiscal year. Gross profit decreased from $29.8 million to $22.6 million, with gross profit margin falling from 19.6% to 17.8%. Net loss widened from $14.8 million to $39.2 million.

Key points:

 

·Income Decline: In the 2025 fiscal year, Ispire Technology's operating income was $127.5 million, a 16.1% decrease from the $151.9 million in the 2024 fiscal year. 

·Gross profit and gross margin decrease: Gross profit decreased from $29.8 million to $22.6 million, with the gross margin decreasing from 19.6% to 17.8%. 

·Net loss expands: The net loss expanded from $14.8 million to $39.2 million. 

·Strategic transformation: The company continues to transition from the cannabis industry to the nicotine sector.

 


 

On September 17, 2025 - According to a report on the Ispire Technology website on September 16, Ispire Technology Inc. (NASDAQ: ISPR) announced its fiscal year financial report for the period ending on June 30, 2025. The report showed that the company's revenue for the 2025 fiscal year was $127.5 million, a decrease from $151.9 million in the previous fiscal year. Gross profit decreased from $29.8 million in the previous fiscal year to $22.6 million, with a gross profit margin dropping from 19.6% to 17.8%. Net losses widened from $14.8 million in the previous fiscal year to $39.2 million. As of June 30, 2025, the company held cash and cash equivalents of $24.4 million, with operating capital of $400,000.

 

In the 2025 fiscal year, Ispire's revenue was $127.5 million, a decrease from $151.9 million in the 2024 fiscal year. This decline is primarily due to the company's strategic repositioning from the cannabis sector to the nicotine sector, despite the aim of achieving more sustainable long-term growth through this transition. Gross profit decreased from $29.8 million in the previous fiscal year to $22.6 million, with a gross margin drop from 19.6% to 17.8%. Total operating expenses increased from $43.7 million in 2024 to $60.5 million, mainly due to higher sales and marketing expenses and an increase in expected credit losses on accounts receivable.

 

The net loss expanded from $14.8 million in the 2024 fiscal year to $39.2 million in the 2025 fiscal year. This increase in loss reflects the challenges the company is facing during its strategic transformation, including increased operational expenses and declining revenues. As of June 30, 2025, the company held $24.4 million in cash and cash equivalents, with operating capital of $400,000.

 

Ispire Co-CEO Michael Wang said, "The 2025 fiscal year is a crucial period for Ispire's strategic transformation as we continue to shift our focus from the cannabis industry to the higher value nicotine industry. We have made sound strategic decisions, prioritizing quality customers over quantity, and repositioning our business for sustainable growth while prioritizing long-term partnerships. Our investments in groundbreaking technologies, including IKE Tech LLC and G-Mesh technology, are gaining favor with major tobacco companies as these innovative technologies go through regulatory approval processes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

InterTabac 2026: First conference program highlights now available online
InterTabac 2026: First conference program highlights now available online
With three months to go before the international tobacco and nicotine industry gathers again in Dortmund, InterTabac, together with NUBIZ and InterSupply, is set to bring around 800 exhibitors from across the globe to eleven exhibition halls. The three events will showcase innovation, market trends and industry networking, while the first conference program highlights are now online, offering trade visitors keynotes, panel discussions and masterclasses to support business decision-making.
Events
Jun.22
 BAT Bangladesh Cigarette Sales Fall 14%, Q1 Profit Drops 34%
BAT Bangladesh Cigarette Sales Fall 14%, Q1 Profit Drops 34%
British American Tobacco Bangladesh reported a 14% year-on-year decline in cigarette sales volume and a 34% drop in first-quarter profit, highlighting mounting pressure from inflation, taxation, and weakening consumer spending in Bangladesh.
News
May.18
BAT Estimates U.S. Unauthorized Vape Market at $9.4 Billion, Plans New Vuse and Velo Launches After FDA Enforcement Shift
BAT Estimates U.S. Unauthorized Vape Market at $9.4 Billion, Plans New Vuse and Velo Launches After FDA Enforcement Shift
British American Tobacco (BAT) CEO Tadeu Marroco said the U.S. unauthorized vape market is worth about £7 billion, or US$9.43 billion. Following a shift in FDA enforcement policy, BAT plans to launch flavored Vuse products in the third quarter and an updated Velo pouch in August or September.
Jun.15
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary resigned on May 12 after opposing the Trump administration’s push to authorize fruit-flavored vaping products, according to reporting by The New York Times. Makary reportedly objected over concerns that flavored vapes could attract young people and refused to support broader approvals.
News
May.13
Charlie’s Plans Q3 2026 Pilot of America’s First Age-Gated Flavored Disposable Vape
Charlie’s Plans Q3 2026 Pilot of America’s First Age-Gated Flavored Disposable Vape
U.S. vape company Charlie’s Holdings announced plans to pilot its age-gated flavored disposable vape products in hundreds of retail stores during the third quarter of 2026. The company said the products will utilize AI- and blockchain-powered age-verification technology designed to address FDA concerns over youth access and potentially create a new compliance pathway for flavored vape products.
Jun.15
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
The U.S. Food and Drug Administration (FDA) recently authorized two fruit-flavored vaping products from Glas, but a newly released agency memo shows the products did not demonstrate greater smoking-cessation benefits than tobacco-flavored e-cigarettes. The Associated Press said the findings are likely to raise further questions about the FDA’s regulatory rationale and standards for flavored vaping products.
Jun.12